Danvatirsen, also known as AZD9150, is an antisense oligonucleotide that targets signal transducer and activator of transcription 3 (STAT3). Let’s explore more about it:
What Is Danvatirsen?
Danvatirsen is a 16-nucleotide antisense oligonucleotide.
Danvatirsen, also known as AZD9150, is an antisense oligonucleotide that targets signal transducer and activator of transcription 3 (STAT3). Let’s explore more about it:
What Is Danvatirsen?
Danvatirsen is a 16-nucleotide antisense oligonucleotide.
It selectively binds to STAT3 mRNA, inhibiting its translation.
By downregulating STAT3 expression, it induces tumor cell apoptosis and reduces tumor growth12.
Clinical Studies and Applications:
Safety and Tolerability: A phase 1 study in Japanese patients with advanced solid malignancies evaluated danvatirsen monotherapy and danvatirsen combined with durvalumab (an anti-PD-L1 monoclonal antibody). Common adverse events included platelet count decrease and liver enzyme elevation1.
Antitumor Activity: Early clinical evidence suggests that danvatirsen may have clinical benefit when used alone or in combination with durvalumab3.
Non-Small Cell Lung Cancer: Danvatirsen is currently in Phase II clinical development for non-small cell lung cancer4.
Mechanism of Action:
Danvatirsen selectively targets human STAT3, a key regulator of immune suppression in the tumor microenvironment.
It enhances antigen-presenting cell function and modulates tumor cell proliferation1.
In summary, danvatirsen holds promise as a potential antitumor agent, particularly in combination with other therapies. However, further research is needed to establish its efficacy and safety
Any thoughts?
Danvatirsen, also known as AZD9150, is an antisense oligonucleotide that targets signal transducer and activator of transcription 3 (STAT3). Let’s explore more about it:
What Is Danvatirsen?
Danvatirsen is a 16-nucleotide antisense oligonucleotide.
It selectively binds to STAT3 mRNA, inhibiting its translation.
By downregulating STAT3 expression, it induces tumor cell apoptosis and reduces tumor growth12.
Clinical Studies and Applications:
Safety and Tolerability: A phase 1 study in Japanese patients with advanced solid malignancies evaluated danvatirsen monotherapy and danvatirsen combined with durvalumab (an anti-PD-L1 monoclonal antibody). Common adverse events included platelet count decrease and liver enzyme elevation1.
Antitumor Activity: Early clinical evidence suggests that danvatirsen may have clinical benefit when used alone or in combination with durvalumab3.
Non-Small Cell Lung Cancer: Danvatirsen is currently in Phase II clinical development for non-small cell lung cancer4.
Mechanism of Action:
Danvatirsen selectively targets human STAT3, a key regulator of immune suppression in the tumor microenvironment.
It enhances antigen-presenting cell function and modulates tumor cell proliferation1.
In summary, danvatirsen holds promise as a potential antitumor agent, particularly in combination with other therapies. However, further research is needed to establish its efficacy and safety